| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1029026219 |
| P356 | DOI | 10.1038/28204 |
| P3181 | OpenCitations bibliographic resource ID | 1865470 |
| P698 | PubMed publication ID | 9671306 |
| P2093 | author name string | G K Sukhova | |
| P Libby | |||
| E Atkinson | |||
| F Mach | |||
| U Schönbeck | |||
| P2860 | cites work | The pathogenesis of atherosclerosis: a perspective for the 1990s | Q29547827 |
| Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery | Q29615235 | ||
| Diet-induced hypercholesterolemia in mice: prevention by overexpression of LDL receptors | Q34263181 | ||
| Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology | Q34308581 | ||
| CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. | Q34324146 | ||
| CD40/CD40 ligand interactions are required for T cell-dependent production of interleukin-12 by mouse macrophages | Q34732969 | ||
| Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis | Q36028683 | ||
| T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse | Q36142970 | ||
| Functional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediated signals | Q36365548 | ||
| The pathogenesis of coronary artery disease and the acute coronary syndromes (1). | Q36728740 | ||
| Absence of P-selectin delays fatty streak formation in mice | Q37364649 | ||
| CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis | Q37696199 | ||
| Immune regulation by CD40 and its ligand GP39. | Q41039754 | ||
| Expression of functional CD40 by vascular endothelial cells | Q41981036 | ||
| Localization of T lymphocytes and macrophages in fibrous and complicated human atherosclerotic plaques | Q44793358 | ||
| Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. | Q52526594 | ||
| Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? | Q52527039 | ||
| Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways | Q56908985 | ||
| Lymphocyte populations in atherosclerotic lesions of apoE -/- and LDL receptor -/- mice. Decreasing density with disease progression | Q71231739 | ||
| Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40 | Q72093299 | ||
| Impairment of excitatory amino acid transporter activity by oxidative stress conditions in retinal cells: effect of antioxidants | Q73088182 | ||
| Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival | Q74015557 | ||
| Are we mortgaging the medical profession? | Q95814757 | ||
| P433 | issue | 6689 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | atherosclerosis | Q12252367 |
| P304 | page(s) | 200-3 | |
| P577 | publication date | 1998-07-09 | |
| P1433 | published in | Nature | Q180445 |
| P1476 | title | Reduction of atherosclerosis in mice by inhibition of CD40 signalling | |
| P478 | volume | 394 |
| Q41824616 | A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation |
| Q34416243 | A journey in science: medical scientist in translation |
| Q37765287 | A timely diagnosis of myocardial infarction. |
| Q38737500 | ATVB Distinguished Scientist Award: How Costimulatory and Coinhibitory Pathways Shape Atherosclerosis |
| Q37407750 | Abrogated transforming growth factor beta receptor II (TGFβRII) signalling in dendritic cells promotes immune reactivity of T cells resulting in enhanced atherosclerosis. |
| Q34601733 | Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? |
| Q37277926 | Acute coronary syndromes: from the laboratory markers to the coronary vessels |
| Q37866627 | Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets |
| Q35581561 | Adhesion molecules and atherosclerosis |
| Q34368686 | Advances in experimental dyslipidemia and atherosclerosis |
| Q33903180 | Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway |
| Q73086611 | Anti-atherogenic effect of coenzyme Q10 in apolipoprotein E gene knockout mice |
| Q34790028 | Anti-beta 2-glycoprotein I autoantibodies and atherosclerosis |
| Q38349757 | Anti-inflammatory therapies for atherosclerosis |
| Q58481433 | Antiplatelet drugs |
| Q73355679 | Aortic recruitment of blood lymphocytes is most pronounced in early stages of lesion formation in apolipoprotein-E-deficient mice |
| Q88235115 | Association of CD40 Gene Polymorphisms with Susceptibility to Neuromyelitis Optica Spectrum Disorders |
| Q83921113 | Association of soluble CD40 ligand with carotid atherosclerosis in Japanese type 1 diabetic patients |
| Q79978197 | Asymptomatic kindred of patients with coronary events have increased peripheral T-cell activities |
| Q37378106 | Atherosclerosis in autoimmune diseases |
| Q29618972 | Atherosclerosis. the road ahead |
| Q36216095 | Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system |
| Q35063770 | Atherosclerotic plaque formation and risk factors |
| Q33694775 | Atherosclerotic plaque rupture: emerging insights and opportunities |
| Q35788328 | Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions |
| Q37283009 | Autoimmune-mediated atherothrombosis |
| Q28710388 | Autoreactive HSP60 epitope-specific T-cells in early human atherosclerotic lesions |
| Q93052209 | B Cell and CD4 T Cell Interactions Promote Development of Atherosclerosis |
| Q34618889 | Basic science review: Statin therapy--Part I: The pleiotropic effects of statins in cardiovascular disease |
| Q35144122 | Beta3 integrin deficiency promotes atherosclerosis and pulmonary inflammation in high-fat-fed, hyperlipidemic mice |
| Q35808632 | Beyond cholesterol--inflammatory cytokines, the key mediators in atherosclerosis |
| Q35795164 | Binding of CD40L to Mac-1's I-domain involves the EQLKKSKTL motif and mediates leukocyte recruitment and atherosclerosis--but does not affect immunity and thrombosis in mice |
| Q35938537 | Biomarkers of cardiac disease |
| Q55175817 | Biomimetic nanoparticles for inflammation targeting. |
| Q38972708 | Blockade of CD40-TRAF2,3 or CD40-TRAF6 is sufficient to inhibit pro-inflammatory responses in non-haematopoietic cells |
| Q35161070 | Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype |
| Q33843636 | C-reactive protein, inflammation, and coronary risk |
| Q79299389 | C-reactive protein, inflammation, and coronary risk |
| Q35787847 | CD1 expression in human atherosclerosis. A potential mechanism for T cell activation by foam cells |
| Q35176320 | CD154 transcriptional regulation in primary human CD4 T cells |
| Q40919282 | CD154-CD40 T-cell co-stimulation pathway is a key mechanism in kidney ischemia-reperfusion injury |
| Q50089678 | CD27 co-stimulation increases the abundance of regulatory T cells and reduces atherosclerosis in hyperlipidaemic mice. |
| Q40256254 | CD40 Generation 2.5 Antisense Oligonucleotide Treatment Attenuates Doxorubicin-induced Nephropathy and Kidney Inflammation. |
| Q28166057 | CD40 Ligand-Dependent Maturation of Human Monocyte-Derived Dendritic Cells by Activated Platelets |
| Q47626387 | CD40 and CD40L expression in the chicken embryo aorta: possible role in the endothelial-mesenchymal transdifferentiation process |
| Q36836306 | CD40 deficiency in mice exacerbates obesity-induced adipose tissue inflammation, hepatic steatosis, and insulin resistance |
| Q48415768 | CD40 expressed by human brain endothelial cells regulates CD4+ T cell adhesion to endothelium. |
| Q26752784 | CD40 in coronary artery disease: a matter of macrophages? |
| Q34005419 | CD40 is essential in the upregulation of TRAF proteins and NF-kappaB-dependent proinflammatory gene expression after arterial injury |
| Q28288474 | CD40 ligand as a potential biomarker for atherosclerotic instability |
| Q52949259 | CD40 ligand is selectively expressed on CD4+ T cells and platelets: implications for CD40–CD40L signalling in atherosclerosis |
| Q30441065 | CD40 ligand promotes Mac-1 expression, leukocyte recruitment, and neointima formation after vascular injury |
| Q43129374 | CD40 ligand shedding is regulated by interaction between matrix metalloproteinase-2 and platelet integrin alpha(IIb)beta(3). |
| Q35793488 | CD40 ligation induces tissue factor expression in human vascular smooth muscle cells |
| Q37111264 | CD40 promotes MHC class II expression on adipose tissue macrophages and regulates adipose tissue CD4+ T cells with obesity. |
| Q34919840 | CD40 promotes the development of early diabetic retinopathy in mice |
| Q35788667 | CD40-CD40 ligand disruption does not prevent hyperoxia-induced injury |
| Q38042321 | CD40-CD40L: linking pancreatic, adipose tissue and vascular inflammation in type 2 diabetes and its complications |
| Q35879683 | CD40-TRAF Signaling Upregulates CX3CL1 and TNF-α in Human Aortic Endothelial Cells but Not in Retinal Endothelial Cells |
| Q44362136 | CD40-dependent activation of phosphatidylinositol 3-kinase/Akt pathway mediates endothelial cell survival and in vitro angiogenesis. |
| Q37138961 | CD40/CD40L contributes to hypercholesterolemia-induced microvascular inflammation |
| Q33814059 | CD40L and Its Receptors in Atherothrombosis-An Update |
| Q34193651 | CD40L deficiency attenuates diet-induced adipose tissue inflammation by impairing immune cell accumulation and production of pathogenic IgG-antibodies |
| Q79116704 | Can we stabilize unstable plaque? |
| Q24568066 | Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis |
| Q35197222 | Cardiovascular complications in inflammatory bowel disease. |
| Q36809182 | Cardiovascular disease, inflammation, and periodontal infection |
| Q28245234 | Cathepsin G activity lowers plasma LDL and reduces atherosclerosis |
| Q35544330 | Cellular adhesion molecules and cardiovascular disease. Part II. Their association with conventional and emerging risk factors, acute coronary events and cardiovascular risk prediction |
| Q46694569 | Chemical analysis of atherosclerotic plaque cholesterol combined with histology of the same tissue |
| Q58246532 | Chemokines and atherosclerosis |
| Q37874834 | Chlamydia pneumoniae infection significantly exacerbates aortic atherosclerosis in an LDLR-/- mouse model within six months. |
| Q37035672 | Clinical correlates, heritability, and genetic linkage of circulating CD40 ligand in the Framingham Offspring Study |
| Q28218124 | Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease |
| Q43581222 | Clinical significance of brachial flow-mediated dilation in patients with rheumatoid arthritis |
| Q42725474 | Clopidogrel for the hot patient |
| Q35181668 | Contact-dependent signaling during the late events of platelet activation. |
| Q36491362 | Control of canonical NF-kappaB activation through the NIK-IKK complex pathway |
| Q38025388 | Control of dichotomic innate and adaptive immune responses by artery tertiary lymphoid organs in atherosclerosis. |
| Q37429889 | Cytokine network and T cell immunity in atherosclerosis |
| Q28570672 | Cytokine-inducible CD40 gene expression in vascular smooth muscle cells is mediated by nuclear factor kappaB and signal transducer and activation of transcription-1 |
| Q34967612 | Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice |
| Q33656103 | Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile |
| Q89976448 | Development of Fractalkine-Targeted Nanofibers that Localize to Sites of Arterial Injury |
| Q24563090 | Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells |
| Q36524547 | Disruption of TGF-β signaling in T cells accelerates atherosclerosis |
| Q21285000 | Diverse roles of macrophages in atherosclerosis: from inflammatory biology to biomarker discovery |
| Q35133174 | Dynamic changes in regulatory T cells are linked to levels of diet-induced hypercholesterolemia |
| Q30405805 | Dysregulated CD4+ T cells from SLE-susceptible mice are sufficient to accelerate atherosclerosis in LDLr-/- mice |
| Q28214364 | Effects of VasoCare therapy on the initiation and progression of atherosclerosis |
| Q63560435 | Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates |
| Q37361364 | Elevated frequencies of circulating Th22 cell in addition to Th17 cell and Th17/Th1 cell in patients with acute coronary syndrome |
| Q46820939 | Elevated release of sCD40L from platelets of diabetic patients by thrombin, glucose and advanced glycation end products |
| Q43939775 | Elevated soluble CD40 ligand is related to the endothelial adhesion molecules in patients with acute coronary syndrome |
| Q34455024 | Endogenous heparin activity deficiency: the 'missing link' in atherogenesis? |
| Q43977294 | Endothelial cell and cAMP regulation of T-cell CD40 ligand: relevance of calcium/calmodulin-dependent kinase IV signalling |
| Q46469540 | Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control. |
| Q51813174 | Enhanced soluble CD40L in patients with the metabolic syndrome: Relationship with in vivo thrombin generation. |
| Q37576750 | Experimental immunotherapeutic approaches for atherosclerosis. |
| Q37167792 | Experimental models investigating the inflammatory basis of atherosclerosis |
| Q42857233 | Expression and cellular localization of the CC chemokines PARC and ELC in human atherosclerotic plaques |
| Q56906591 | Expression of CD40 and its ligand, CD40L, in intestinal lesions of Crohn's disease |
| Q73344118 | Expression of CD40 in vascular smooth muscle cells and macrophages is associated with early development of human atherosclerotic lesions |
| Q35747016 | Expression of interleukin-15 in mouse and human atherosclerotic lesions |
| Q36367835 | Expression of stromelysin-3 in atherosclerotic lesions: regulation via CD40-CD40 ligand signaling in vitro and in vivo |
| Q73667820 | Function of CD40/CD40L in peritubular capillary of renal allograft rejection |
| Q40025338 | Functional analysis of a tripartite stability element within the CD40 ligand 3' untranslated region |
| Q33762089 | Functionality of specific immunity in atherosclerosis |
| Q36753593 | Future innovations in anti-platelet therapies. |
| Q45237822 | GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention |
| Q35975437 | Genetic basis of atherosclerosis: insights from mice and humans |
| Q34080318 | Genetic modifiers of atherosclerosis in mice |
| Q36691050 | Genetically programmed biases in Th1 and Th2 immune responses modulate atherogenesis |
| Q43596820 | Geneva Biology of Ageing Workshop 2000: phagocytes, inflammation, and ageing |
| Q35551274 | High titres of serum antinuclear antibodies, mostly directed against nucleolar antigens, are associated with the presence of coronary atherosclerosis |
| Q37983656 | Humoral and cellular immune responses in atherosclerosis: spotlight on B- and T-cells |
| Q52938547 | IFN-alpha enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells. |
| Q42556810 | Identification of primary retinal cells and ex vivo detection of proinflammatory molecules using flow cytometry |
| Q37699812 | Imbalance between endothelial damage and repair: a gateway to cardiovascular disease in systemic lupus erythematosus. |
| Q37325024 | Immune and inflammatory mechanisms of atherosclerosis (*) |
| Q34006304 | Immunological responses to oxidized LDL. |
| Q35753555 | Immunomodulation and vaccination for atherosclerosis |
| Q35172183 | Immunomodulation for treatment and prevention of atherosclerosis |
| Q33890414 | Immunomodulation of atherosclerosis: myth and reality. |
| Q35994774 | Immunotherapy targeting the CD40/CD154 costimulatory pathway for treatment of autoimmune disease |
| Q31132267 | Impact of glutathione peroxidase-1 deficiency on macrophage foam cell formation and proliferation: implications for atherogenesis |
| Q37307577 | Impact of high fat diet on long non-coding RNAs and messenger RNAs expression in the aortas of ApoE(-/-) mice |
| Q58796242 | Implication of miR-612 and miR-1976 in the regulation of TP53 and CD40 and their relationship in the response to specific weight-loss diets |
| Q57718046 | Increased concentrations of soluble CD40 ligand may help to identify type 1 diabetic adolescents and young adults at risk for developing persistent microalbuminuria |
| Q44854404 | Increased soluble CD40 ligand levels in cystic fibrosis |
| Q33183763 | Induction of cyclooxygenase-2 and enhanced release of prostaglandin E(2) and I(2) in human endothelial cells by engagement of CD40. |
| Q34107230 | Inflammation and immune response in atherosclerosis |
| Q38083555 | Inflammation and immune system interactions in atherosclerosis |
| Q33871329 | Inflammation, infection and atherosclerosis: do antibacterials have a role in the therapy of coronary artery disease? |
| Q35549285 | Inflammation-mediated rheumatic diseases and atherosclerosis |
| Q39062398 | Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis. |
| Q33805176 | Inflammatory and autoimmune reactions in atherosclerosis and vaccine design informatics |
| Q34941391 | Inflammatory bio-markers and cardiovascular risk prediction |
| Q35160907 | Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice |
| Q34960144 | Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis |
| Q34986341 | Innate and acquired immunity in atherogenesis |
| Q33659705 | Innate and adaptive immunity in atherosclerosis |
| Q47222500 | Insulin-Like Growth Factor 1 in the Cardiovascular System. |
| Q34360578 | Integrin tyrosine phosphorylation in platelet signaling |
| Q59064332 | Interferon-γ elicits arteriosclerosis in the absence of leukocytes |
| Q28771509 | Interleukin 18 function in atherosclerosis is mediated by the interleukin 18 receptor and the Na-Cl co-transporter |
| Q47599422 | Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond |
| Q38023144 | Intimal hyperplasia: slow but deadly |
| Q36359710 | Intravenous immunoglobulin and atherosclerosis |
| Q51959245 | Inverse correlation between soluble CD40 ligand and soluble CD40 is absent in patients with unstable angina. |
| Q35787744 | Kruppel-Like Factor 2-Mediated Suppression of MicroRNA-155 Reduces the Proinflammatory Activation of Macrophages |
| Q80693835 | Leptin induces CD40 expression through the activation of Akt in murine dendritic cells |
| Q36072647 | Lymphocytes are important in early atherosclerosis |
| Q33184773 | MCMV infection increases early T-lymphocyte influx in atherosclerotic lesions in apoE knockout mice |
| Q34236802 | Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice |
| Q80422792 | Mast cells promote atherosclerosis by releasing proinflammatory cytokines |
| Q34655385 | Matrix metalloproteinases and atherosclerotic plaque instability |
| Q35602333 | Mechanisms of Nifedipine-Downregulated CD40L/sCD40L Signaling in Collagen Stimulated Human Platelets |
| Q37072381 | Mechanisms of disease: macrophage migration inhibitory factor in SLE, RA and atherosclerosis |
| Q33835268 | Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis |
| Q74702825 | Metabolism of oxidized and chemically modified low density lipoproteins in rainbow trout--clearance via scavenger receptors |
| Q39454807 | Metabolism-associated danger signal-induced immune response and reverse immune checkpoint-activated CD40+ monocyte differentiation |
| Q34630514 | Microvascular thrombosis and CD40/CD40L signaling |
| Q34160242 | Minding the gaps to promote thrombus growth and stability |
| Q36209119 | Molecular aspects of thrombosis and antithrombotic drugs |
| Q33946830 | Molecular link between cholesterol, cytokines and atherosclerosis |
| Q34772143 | Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease |
| Q38176479 | Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases |
| Q52541865 | Multiple mechanisms of thrombosis complicating atherosclerotic plaques. |
| Q57839864 | Mycophenolate mofetil as an immunomodulatory silver bullet in atherogenesis? |
| Q36385620 | Myocardial infarction mediated by endothelin receptor signaling in hypercholesterolemic mice |
| Q93106450 | Na+-H+ exchanger 1 determines atherosclerotic lesion acidification and promotes atherogenesis |
| Q36375728 | Neonatal tumor necrosis factor alpha promotes diabetes in nonobese diabetic mice by CD154-independent antigen presentation to CD8(+) T cells. |
| Q28211342 | New Markers of Inflammation and Endothelial Cell Activation |
| Q43182095 | New frontiers for platelet CD154. |
| Q34787127 | Normal Th1 development following long-term therapeutic blockade of CD154-CD40 in experimental autoimmune encephalomyelitis |
| Q46212010 | Novel role of the CXC chemokine receptor 3 in inflammatory response to arterial injury: involvement of mTORC1. |
| Q36508895 | Nuclear factor of activated T cells (NFAT) mediates CD154 expression in megakaryocytes |
| Q37005645 | Nuclear receptors in macrophages: a link between metabolism and inflammation. |
| Q28192292 | Opportunities for the treatment of inflammation in cardiovascular disease |
| Q31075609 | Overexpression of TGF-ß1 in macrophages reduces and stabilizes atherosclerotic plaques in ApoE-deficient mice |
| Q33554184 | Oxidative risk for atherothrombotic cardiovascular disease |
| Q37387741 | Oxidized LDL activates fas-mediated endothelial cell apoptosis |
| Q36375890 | P-Selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice |
| Q35838444 | P-selectin in haemostasis |
| Q44720878 | P-selectin, tissue factor and CD40 ligand expression on platelet-leucocyte conjugates in the presence of a GPIIb/IIIa antagonist |
| Q46840844 | PARP1 is required for adhesion molecule expression in atherogenesis |
| Q50848490 | PKC-epsilon and TLR4 synergistically regulate resistin-mediated inflammation in human macrophages. |
| Q33183129 | Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. |
| Q37047173 | Pharmaceutical stabilization of mast cells attenuates experimental atherogenesis in low-density lipoprotein receptor-deficient mice |
| Q34647991 | Plasma concentrations of soluble CD40 ligand in smokers with acute myocardial infarction: a pilot study |
| Q47645034 | Platelet CD40 Mediates Leukocyte Recruitment and Neointima Formation after Arterial Denudation Injury in Atherosclerosis-Prone Mice |
| Q30497499 | Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis |
| Q49082878 | Platelet and monocyte activation in acute ischemic stroke--is there a correlation with stroke etiology? |
| Q37131719 | Platelet chemokines in vascular disease |
| Q37058252 | Platelet-lymphocyte cross-talk |
| Q39125083 | Platelets and von Willebrand factor in atherogenesis |
| Q34263823 | Platelets in Inflammation and Thrombosis |
| Q36328825 | Platelets in inflammation and atherogenesis. |
| Q35570940 | Platelets, atherosclerosis and the endothelium: new therapeutic targets? |
| Q46367698 | Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome |
| Q34795130 | Proinflammatory responses induced by CD40 in retinal endothelial and Müller cells are inhibited by blocking CD40-Traf2,3 or CD40-Traf6 signaling |
| Q36452637 | Proinflammatory, immunomodulating, and prothrombotic properties of anemia and red blood cell transfusions |
| Q50441470 | Propolis and swimming in the prevention of atherogenesis and left ventricular hypertrophy in hypercholesterolemic mice. |
| Q34789613 | Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice |
| Q44283435 | Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy |
| Q51550263 | Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. |
| Q34101903 | Regulation of CD40 function by its isoforms generated through alternative splicing |
| Q38396097 | Regulation of atherosclerotic plaque inflammation |
| Q28221912 | Release of biologically active CD154 during collection and storage of platelet concentrates prepared for transfusion |
| Q52536870 | Requirement for CD154 in the progression of atherosclerosis. |
| Q35691984 | Risk Stratification in Patients with Unstable Angina and Non-ST-elevation Myocardial Infarction |
| Q64894351 | Role of CD40 and ADAMTS13 in von Willebrand factor-mediated endothelial cell-platelet-monocyte interaction. |
| Q35541858 | Role of Monocytes in Atherogenesis |
| Q34963016 | Role of RANKL and RANK in bone loss and arthritis. |
| Q37080012 | Role of cell adhesion molecules and immune-cell migration in the initiation, onset and development of atherosclerosis |
| Q36135534 | SLE, atherosclerosis and cardiovascular disease |
| Q37218397 | Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome |
| Q35633740 | Soluble CD40 ligand as a predictor of coronary artery disease and long-term clinical outcomes in stable patients undergoing coronary angiography |
| Q36941078 | Soluble CD40 ligand induces endothelial dysfunction in human and porcine coronary artery endothelial cells |
| Q36350146 | Soluble CD40 ligand induces β 3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling |
| Q51498412 | Soluble CD40L in patients with morbid obesity: significant reduction after bariatric surgery. |
| Q37027316 | Statin treatment for rheumatoid arthritis: a promising novel indication |
| Q37585835 | Sympathetic overstimulation during critical illness: adverse effects of adrenergic stress |
| Q43419630 | Systemic lupus erythematosus and cardiovascular disease |
| Q63915433 | T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword |
| Q28396774 | T cell costimulatory and coinhibitory pathways in vascular inflammatory diseases |
| Q35067512 | T cell-specific overexpression of TGFß1 fails to influence atherosclerosis in ApoE-deficient mice |
| Q34108813 | T cells in the pathogenesis of systemic lupus erythematosus: potential roles of CD154-CD40 interactions and costimulatory molecules |
| Q37875919 | T lymphocyte lines isolated from atheromatous plaque contain cells capable of responding to Chlamydia antigens. |
| Q33819043 | T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses |
| Q40347857 | T-cell co-stimulators as anti-inflammatory targets for atherosclerotic disease |
| Q37143018 | T-cell costimulation and coinhibition in atherosclerosis. |
| Q36368029 | TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation |
| Q37494039 | TWEAK/Fn14 Axis: A Promising Target for the Treatment of Cardiovascular Diseases. |
| Q49369729 | Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis. |
| Q38406177 | Targeting the adaptive immune system: new strategies in the treatment of atherosclerosis |
| Q92538952 | The CD40-ATP-P2X 7 Receptor Pathway: Cell to Cell Cross-Talk to Promote Inflammation and Programmed Cell Death of Endothelial Cells |
| Q37829738 | The CD40-CD40L system in cardiovascular disease. |
| Q47245105 | The CD40-TRAF6 axis is the key regulator of the CD40/CD40L system in neointima formation and arterial remodeling |
| Q49993738 | The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis. |
| Q34054032 | The Levels of Inflammatory Markers in the Treatment of Stroke study (LIMITS): inflammatory biomarkers as risk predictors after lacunar stroke |
| Q37560012 | The Role of Immunogenicity in Cardiovascular Disease |
| Q40452360 | The atheroprotective properties of Hsp70: a role for Hsp70-endothelial interactions? |
| Q92983665 | The dual role of platelet-innate immune cell interactions in thrombo-inflammation |
| Q36508676 | The immune response in atherosclerosis: a double-edged sword |
| Q34164644 | The immune system in atherosclerosis |
| Q27000370 | The influence of innate and adaptive immune responses on atherosclerosis |
| Q33814962 | The initiation of autoimmune diabetes |
| Q83179418 | The involvement of the CD40-CD40L pathway in activated platelet-induced changes in HUVEC COX-2 and PPARα expression |
| Q34020389 | The levels of soluble CD40 ligand and C-reactive protein in normal weight, overweight and obese people |
| Q42514630 | The role of Sp1 and NF-kappa B in regulating CD40 gene expression |
| Q34207434 | The role of chemokines in atherosclerosis |
| Q26996707 | The role of costimulatory receptors of the tumour necrosis factor receptor family in atherosclerosis |
| Q46343438 | The role of monocyte-derived cells and inflammation in baboon ductus arteriosus remodeling |
| Q48175299 | The role of monocytosis and neutrophilia in atherosclerosis |
| Q26801407 | The role of platelets in the recruitment of leukocytes during vascular disease |
| Q40393639 | The use of MCP-1 and soluble CD40 ligand in a pathophysiology-guided approach to the management of coronary artery disease |
| Q37264355 | The value of biochemical markers for risk stratification prior to hospital admission in acute chest pain |
| Q28187576 | Therapeutic approaches in arterial thrombosis |
| Q34074837 | Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis |
| Q33678336 | Toll-like receptor 7 deficiency protects apolipoprotein E-deficient mice from diet-induced atherosclerosis |
| Q35542584 | Towards understanding acute destabilization of vulnerable atherosclerotic plaques |
| Q52543155 | Transcriptome analysis reveals a role of interferon-gamma in human neointima formation. |
| Q33700652 | Triglyceride-rich lipoproteins: are links with atherosclerosis mediated by a procoagulant and proinflammatory phenotype? |
| Q34369244 | Tumor necrosis factor receptor-associated factor 1 (TRAF1) deficiency attenuates atherosclerosis in mice by impairing monocyte recruitment to the vessel wall |
| Q38294592 | Upregulation of TRAF-3 by shear stress blocks CD40-mediated endothelial activation |
| Q35692035 | Vaccination and atherosclerosis |
| Q30444108 | Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice |
| Q35088517 | Vascular biology of atherosclerosis: overview and state of the art. |
| Q30319434 | Vascular cells contribute to atherosclerosis by cytokine- and innate-immunity-related inflammatory mechanisms |
| Q34514026 | Vascular inflammation as a therapeutic target for prevention of cardiovascular disease |
| Q82893705 | [Immunological aspects of atherosclerosis] |
| Q53868946 | [Interleukin-10 and coronary disease]. |
Search more.